Artificial Intelligence in Drug Discovery Market - Global Forecast to 2029

Table of Content

1 INTRODUCTION 39
1.1 STUDY OBJECTIVES 39
1.2 MARKET DEFINITION 39
1.3 STUDY SCOPE 40
1.3.1 SEGMENTS AND REGIONS CONSIDERED 40
1.3.2 INCLUSIONS AND EXCLUSIONS 41
1.3.3 YEARS CONSIDERED 42
1.3.4 CURRENCY CONSIDERED 42
1.4 MARKET STAKEHOLDERS 43
1.5 SUMMARY OF CHANGES 44
2 RESEARCH METHODOLOGY 45
2.1 RESEARCH DATA 45
2.1.1 SECONDARY DATA 46
2.1.1.1 Key secondary sources 46
2.1.1.2 Key data from secondary sources 47
2.1.2 PRIMARY DATA 47
2.1.2.1 Key primary sources 48
2.1.2.2 Key objectives of primary research 48
2.1.2.3 Key data from primary sources 49
2.1.2.4 Key industry insights 50
2.1.2.5 Breakdown of primaries 50
2.2 RESEARCH DESIGN 51
2.3 MARKET SIZE ESTIMATION 51
2.3.1 SUPPLY-SIDE ANALYSIS (REVENUE SHARE ANALYSIS) 52
2.3.2 BOTTOM-UP APPROACH: END-USER ADOPTION 54
2.3.2.1 Top-down assessment of parent market 55
2.3.2.2 Company presentations and primary interviews 55
2.4 DATA TRIANGULATION 59
2.5 STUDY ASSUMPTIONS 60
2.5.1 MARKET SIZING ASSUMPTIONS 60
2.5.2 RESEARCH ASSUMPTIONS 60
2.6 RISK ASSESSMENT 61
2.7 RESEARCH LIMITATIONS 61
2.7.1 METHODOLOGY-RELATED LIMITATIONS 61
2.7.2 SCOPE-RELATED LIMITATIONS 61
?
3 EXECUTIVE SUMMARY 62
4 PREMIUM INSIGHTS 68
4.1 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET OVERVIEW 68
4.2 NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET,
BY END USER AND COUNTRY (2023) 69
4.3 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 70
4.4 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET: REGIONAL MIX 71
4.5 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET: DEVELOPED VS.
EMERGING MARKETS 71
5 MARKET OVERVIEW 72
5.1 INTRODUCTION 72
5.2 MARKET DYNAMICS 72
5.2.1 DRIVERS 74
5.2.1.1 Increasing number of cross-industry collaborations and partnerships 74
5.2.1.2 Rising need to reduce time and cost of drug discovery and development 76
5.2.1.3 Patent expiry of drugs and need for effective new leads 76
5.2.1.4 Growing utilization of AI to predict drug-target interactions for cancer therapy 77
5.2.1.5 Integration of AI-assisted multiomics in drug discovery 78
5.2.1.6 Growing focus on rare disease treatments for orphan drug development 79
5.2.2 RESTRAINTS 80
5.2.2.1 Shortage of AI workforce and ambiguous regulatory guidelines for medical software 80
5.2.3 OPPORTUNITIES 81
5.2.3.1 Leveraging AI for accelerated biotech drug discovery 81
5.2.3.2 Increased focus on drug discovery in emerging economies 81
5.2.3.3 Focus on developing human-aware AI systems 82
5.2.3.4 Growing use of AI in single-cell analysis 82
5.2.3.5 Easy identification of biomarker and disease subtypes from single-cell data 83
5.2.3.6 High demand for precision and personalized medicines 84
5.2.4 CHALLENGES 85
5.2.4.1 Limited availability of quality data sets 85
5.2.4.2 Lack of advanced AI tools and training data sets 85
5.2.4.3 Computational constraints of advanced AI models 86
5.2.4.4 Lack of high-quality data sets for model training 86
5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMER’S BUSINESS 87
?
5.4 INDUSTRY TRENDS 87
5.4.1 EVOLUTION OF AI IN DRUG DISCOVERY 87
5.4.2 COMPUTER-AIDED DRUG DESIGN AND ARTIFICIAL INTELLIGENCE 89
5.5 ECOSYSTEM ANALYSIS 91
5.6 SUPPLY CHAIN ANALYSIS 93
5.7 TECHNOLOGY ANALYSIS 94
5.7.1 KEY TECHNOLOGIES 94
5.7.1.1 Dry lab services 94
5.7.1.2 Wet lab services 97
5.7.1.2.1 Chemistry software and services 97
5.7.1.2.2 Biology software and services 98
5.7.1.2.2.1 Single-cell analysis 99
5.7.2 COMPLEMENTARY TECHNOLOGIES 102
5.7.2.1 High-performance computing 102
5.7.2.2 Next-generation sequencing 102
5.7.2.3 Real-world evidence/Real-world data 102
5.7.3 ADJACENT TECHNOLOGIES 103
5.7.3.1 Cloud computing 103
5.7.3.2 Blockchain technologies 103
5.7.3.3 Internet of things 103
5.8 REGULATORY LANDSCAPE 104
5.8.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 104
5.8.2 REGULATORY FRAMEWORK 107
5.9 PRICING ANALYSIS 111
5.9.1 INDICATIVE SELLING PRICE FOR DRUG DISCOVERY SOFTWARE AND SERVICES, BY REGION 111
5.9.2 INDICATIVE PRICING ANALYSIS, BY PROCESS 112
5.10 PORTER’S FIVE FORCES ANALYSIS 112
5.10.1 INTENSITY OF COMPETITIVE RIVALRY 114
5.10.2 BARGAINING POWER OF BUYERS 114
5.10.3 THREAT OF SUBSTITUTES 114
5.10.4 THREAT OF NEW ENTRANTS 114
5.10.5 BARGAINING POWER OF SUPPLIERS 115
5.11 KEY STAKEHOLDERS AND BUYING CRITERIA 115
5.11.1 KEY STAKEHOLDERS IN BUYING PROCESS 115
5.11.2 KEY BUYING CRITERIA 116
5.12 PATENT ANALYSIS 117
5.12.1 PATENT PUBLICATION TRENDS 117
5.12.2 JURISDICTION ANALYSIS: TOP APPLICANT COUNTRIES FOR ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY 117
5.12.3 MAJOR PATENTS IN ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET 119
?
5.13 UNMET NEEDS AND KEY PAIN POINTS 121
5.13.1 UNMET NEEDS 121
5.13.2 SINGLE-CELL ANALYSIS LANDSCAPE: KEY CHALLENGES AND PAIN POINTS IN DRUG DISCOVERY 122
5.13.3 END-USER EXPECTATIONS 123
5.14 KEY CONFERENCES & EVENTS, 2024–2025 124
5.15 CASE STUDY ANALYSIS 125
5.16 BUSINESS MODEL ANALYSIS 130
5.17 INVESTMENT AND FUNDING SCENARIO 132
5.18 IMPACT OF AI/GENERATIVE AI ON ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET 133
5.18.1 TOP USE CASES AND MARKET POTENTIAL 133
5.18.1.1 Key use cases 134
5.18.2 CASE STUDIES OF AI/GENERATIVE AI IMPLEMENTATION 135
5.18.2.1 Case study 1: Accelerated drug discovery with generative AI and streamlined workflows 135
5.18.2.2 Case study 2: Accelerating small-molecule drug discovery with generative AI 135
5.18.3 IMPACT OF AI/GENERATIVE AI ON INTERCONNECTED AND ADJACENT ECOSYSTEMS 136
5.18.3.1 AI in drug discovery market 136
5.18.3.2 Genomics and bioinformatics market 137
5.18.3.3 Life science analytics market 137
5.18.4 USER READINESS AND IMPACT ASSESSMENT 138
5.18.4.1 User readiness 138
5.18.4.1.1 Pharmaceutical companies 138
5.18.4.1.2 Biotechnology companies 138
5.18.4.2 Impact assessment 138
5.18.4.2.1 User A: Pharmaceutical Companies 138
5.18.4.2.1.1 Implementation 138
5.18.4.2.1.2 Impact 139
5.18.4.2.2 User B: Biotechnology companies 139
5.18.4.2.2.1 Implementation 139
5.18.4.2.2.2 Impact 139
5.19 ARTIFICIAL INTELLIGENCE-DERIVED CLINICAL ASSETS 140
6 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY PROCESS 150
6.1 INTRODUCTION 151
6.2 TARGET IDENTIFICATION & SELECTION 152
6.2.1 INCREASED DEMAND FOR PERSONALIZED MEDICINES AND HIGH INVESTMENT IN PHARMACEUTICAL R&D TO FUEL MARKET GROWTH 152
6.3 TARGET VALIDATION 153
6.3.1 RISING EMPHASIS ON AVOIDING LATE-STAGE FAILURE IN DRUG DISCOVERY TO BOOST MARKET GROWTH 153
6.4 HIT IDENTIFICATION & PRIORITIZATION 154
6.4.1 NEED FOR LARGE-SCALE DATA ANALYSIS TO DRIVE ADOPTION 154
6.5 HIT-TO-LEAD IDENTIFICATION/LEAD GENERATION 155
6.5.1 HIT-TO-LEAD IDENTIFICATION/LEAD GENERATION TO IMPROVE NEW DRUG POTENCY WITHOUT INCREASING LIPOPHILICITY 155
6.6 LEAD OPTIMIZATION 156
6.6.1 NEED FOR TRANSPARENT PRESENTATION AND ANALYSIS TO BOOST MARKET GROWTH 156
6.7 CANDIDATE SELECTION & VALIDATION 157
6.7.1 HIGH POSSIBILITY OF CLINICAL DRUG FAILURE TO SPUR ADOPTION OF CANDIDATE VALIDATION SERVICES 157
7 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY USE CASE 159
7.1 INTRODUCTION 160
7.2 UNDERSTANDING DISEASES 161
7.2.1 INCREASED FOCUS ON UNDERSTANDING DISEASES TO IMPROVE RESEARCH DATA QUALITY AND QUANTITY 161
7.3 DRUG REPURPOSING 162
7.3.1 INCREASING NEED FOR COST-EFFECTIVE TREATMENTS AND RISING AVAILABILITY OF BIOMEDICAL DATA TO AID MARKET GROWTH 162
7.4 DE NOVO DRUG DESIGN 163
7.4.1 SMALL-MOLECULE DESIGN 164
7.4.1.1 Increasing use of virtual screening and simulation techniques to drive growth 164
7.4.2 VACCINE DESIGN 165
7.4.2.1 Availability of well-validated AI tools to boost market growth 165
7.4.3 ANTIBODY & OTHER BIOLOGICS DESIGN 165
7.4.3.1 Advancements in protein modeling to propel segment growth 165
7.5 DRUG OPTIMIZATION 166
7.5.1 SMALL-MOLECULE OPTIMIZATION 167
7.5.1.1 Leveraging generative models for identifying potential modifications in molecular structures to aid market growth 167
7.5.2 VACCINE OPTIMIZATION 168
7.5.2.1 Effectively predicting vaccine formulations and adjusting delivery vectors to drive growth 168
7.5.3 ANTIBODY & OTHER BIOLOGICS OPTIMIZATION 169
7.5.3.1 Increasing adoption of machine learning for predicting protein structures to augment segment growth 169
7.6 SAFETY & TOXICITY 170
7.6.1 FOCUS ON ADVANCED OFF-TARGET EFFECT PREDICTION, PK/PD SIMULATION, AND QSP MODELING TO DRIVE MARKET 170
?
8 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET,
BY THERAPEUTIC AREA 172
8.1 INTRODUCTION 173
8.2 ONCOLOGY 173
8.2.1 HIGH PREVALENCE OF CANCER AND SHORTAGE OF EFFECTIVE ONCOLOGY DRUGS TO PROPEL MARKET GROWTH 173
8.3 INFECTIOUS DISEASES 175
8.3.1 RISING EPIDEMIC OUTBREAKS TO BOOST DRUG DISCOVERY ACTIVITY 175
8.4 NEUROLOGY 177
8.4.1 COMPLEX DISEASE DIAGNOSIS AND TREATMENT TO INCREASE ADOPTION OF ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY 177
8.5 METABOLIC DISEASES 178
8.5.1 ROLE OF ARTIFICIAL INTELLIGENCE IN UNCOVERING SMALL-MOLECULE THERAPIES TO DRIVE ADOPTION 178
8.6 CARDIOVASCULAR DISEASES 179
8.6.1 SEDENTARY LIFESTYLES AND HIGH PREVALENCE OF OBESITY TO INCREASE NOVEL DRUG DEVELOPMENT FOR CARDIAC DISEASES 179
8.7 IMMUNOLOGY 180
8.7.1 GROWING DRUG PIPELINE FOR IMMUNOLOGICAL DISORDERS TO FAVOR MARKET GROWTH 180
8.8 MENTAL HEALTH DISORDERS 180
8.8.1 INCREASED OCCURRENCE OF MENTAL HEALTH DISEASES IN DEVELOPED ECONOMIES TO SPUR MARKET GROWTH 180
8.9 OTHER THERAPEUTIC AREAS 181
9 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY PLAYER TYPE 182
9.1 INTRODUCTION 183
9.2 END-TO-END SOLUTION PROVIDERS 183
9.2.1 END-TO-END SOLUTION PROVIDERS TO REDUCE NEED FOR MULTIPLE VENDORS AND ACCELERATE WORKFLOWS 183
9.3 NICHE/POINT SOLUTION PROVIDERS 184
9.3.1 ACCURATE, COST-EFFECTIVE, AND LESS TIME CONSUMPTION TO PROPEL MARKET GROWTH 184
9.4 AI TECHNOLOGY PROVIDERS 185
9.4.1 SPECIALIZED AI CAPABILITIES WITH FULL-SERVICE MANAGEMENT TO SUPPORT MARKET GROWTH 185
9.5 BUSINESS PROCESS SERVICE PROVIDERS 186
9.5.1 BETTER ACCESSIBILITY OF HIGH-QUALITY TOOLS AND LOWER DRUG DEVELOPMENT COSTS TO AID MARKET GROWTH 186
?
10 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY AI TOOL 187
10.1 INTRODUCTION 188
10.2 MACHINE LEARNING 188
10.2.1 DEEP LEARNING 190
10.2.1.1 Reduced number of errors and consistent management of data to augment market growth 190
10.2.1.2 Convolutional neural networks 191
10.2.1.3 Recurrent neural networks 191
10.2.1.4 Generative adversarial networks 191
10.2.1.5 Graph neural networks 191
10.2.1.6 Other deep learning technologies 192
10.2.2 SUPERVISED LEARNING 192
10.2.2.1 Supervised learning to predict drug repositioning and manage high-dimensional datasets 192
10.2.3 REINFORCEMENT LEARNING 193
10.2.3.1 Need to accelerate new molecules and maximize performance to augment segment growth 193
10.2.4 UNSUPERVISED LEARNING 194
10.2.4.1 Unsupervised learning to perform complex tasks, uncover potential drug candidates, and optimize lead compounds 194
10.2.5 OTHER MACHINE LEARNING TECHNOLOGIES 195
10.3 NATURAL LANGUAGE PROCESSING 196
10.3.1 NATURAL LANGUAGE PROCESSING TO IDENTIFY INFORMATION WITHIN UNSTRUCTURED DATA AND ACCELERATE DRUG DISCOVERY 196
10.4 CONTEXT-AWARE PROCESSING & COMPUTING 197
10.4.1 CONTEXT-AWARE COMPUTING TO IMPROVE PREDICTIONS OF PATIENT-SPECIFIC DRUG RESPONSES AND OPTIMIZE THERAPEUTIC INTERVENTIONS 197
10.5 COMPUTER VISION 198
10.5.1 COMPUTER VISION TO ENHANCE DRUG DISCOVERY THROUGH ADVANCED IMAGE PROCESSING 198
10.6 IMAGE ANALYSIS 198
10.6.1 BETTER DRUG DISCOVERY THROUGH IMAGE PROCESSING TECHNIQUES TO SUPPORT MARKET GROWTH 198
11 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY DEPLOYMENT 200
11.1 INTRODUCTION 201
11.2 ON-PREMISES DEPLOYMENT 201
11.2.1 PROVISION OF MULTI-VENDOR ARCHITECTURE AND SECURITY BENEFITS TO DRIVE MARKET 201
11.3 CLOUD-BASED DEPLOYMENT 202
11.3.1 FOCUS ON RESEARCH COLLABORATIONS AND ELIMINATION OF SOFTWARE AND HARDWARE PURCHASING COSTS TO DRIVE MARKET 202
11.4 SAAS-BASED DEPLOYMENT 204
11.4.1 LOWER COSTS, BETTER SECURITY, AND EASIER ACCESS TO AUGMENT MARKET GROWTH 204
12 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER 206
12.1 INTRODUCTION 207
12.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES 207
12.2.1 RISING DEMAND FOR COST-EFFECTIVE DRUG DEVELOPMENT TO PROPEL MARKET GROWTH 207
12.3 CONTRACT RESEARCH ORGANIZATIONS 210
12.3.1 RISING NEED FOR OUTSOURCING IN PHARMACEUTICAL & BIOTECHNOLOGY INDUSTRIES TO AID MARKET GROWTH 210
12.4 RESEARCH CENTERS AND ACADEMIC & GOVERNMENT INSTITUTES 211
12.4.1 FOCUS ON DEVELOPING THERAPEUTIC STRATEGIES AND INNOVATIVE APPROACHES IN DRUG DISCOVERY TO AID MARKET GROWTH 211
13 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY REGION 213
13.1 INTRODUCTION 214
13.2 NORTH AMERICA 214
13.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA 214
13.2.2 US 220
13.2.2.1 US to dominate North American market during study period 220
13.2.3 CANADA 226
13.2.3.1 Emergence of new AI-based startups and high health expenditure to support market growth 226
13.3 EUROPE 231
13.3.1 MACROECONOMIC OUTLOOK FOR EUROPE 232
13.3.2 UK 237
13.3.2.1 Favorable government R&D funding to augment market growth 237
13.3.3 GERMANY 243
13.3.3.1 Presence of advanced medical infrastructure and high focus on personalized medicines to drive market 243
13.3.4 FRANCE 248
13.3.4.1 Strong government support and favorable strategies to propel market growth 248
13.3.5 ITALY 253
13.3.5.1 Advanced pharmaceutical industry and increased focus on life science R&D to fuel market growth 253
13.3.6 SPAIN 258
13.3.6.1 Favorable government initiatives and high investments by pharmaceutical companies to boost market growth 258
13.3.7 REST OF EUROPE 263
13.4 ASIA PACIFIC 269
13.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC 269
13.4.2 JAPAN 275
13.4.2.1 High geriatric population and advanced pharmaceutical research to boost market growth 275
?
13.4.3 CHINA 281
13.4.3.1 Increasing demand for generics and rising government investments to propel market growth 281
13.4.4 INDIA 286
13.4.4.1 Developed IT infrastructure and favorable government initiatives to spur market growth 286
13.4.5 REST OF ASIA PACIFIC 291
13.5 LATIN AMERICA 296
13.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA 297
13.5.2 BRAZIL 302
13.5.2.1 Growing biotechnology sector and increasing governmental initiatives to boost market growth 302
13.5.3 MEXICO 307
13.5.3.1 Favorable government initiatives and high investments by pharmaceutical companies to support market growth 307
13.5.4 REST OF LATIN AMERICA 312
13.6 MIDDLE EAST & AFRICA 317
13.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA 318
13.6.2 GCC COUNTRIES 323
13.6.2.1 Increasing emphasis on personalized medicines and developing healthcare infrastructure to drive market 323
13.6.3 REST OF MIDDLE EAST & AFRICA 328
14 COMPETITIVE LANDSCAPE 334
14.1 INTRODUCTION 334
14.2 KEY PLAYER STRATEGY/RIGHT TO WIN 334
14.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET 334
14.3 REVENUE ANALYSIS, 2019–2023 336
14.4 MARKET SHARE ANALYSIS, 2023 337
14.4.1 RANKING OF KEY MARKET PLAYERS 339
14.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023 340
14.5.1 STARS 340
14.5.2 EMERGING LEADERS 340
14.5.3 PERVASIVE PLAYERS 340
14.5.4 PARTICIPANTS 340
14.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2023 342
14.5.5.1 Company footprint 342
14.5.5.2 Use case footprint 343
14.5.5.3 Process footprint 344
14.5.5.4 Therapeutic area footprint 345
14.5.5.5 Player type footprint 346
14.5.5.6 Deployment mode footprint 347
14.5.5.7 Region footprint 348
14.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023 349
14.6.1 PROGRESSIVE COMPANIES 349
14.6.2 RESPONSIVE COMPANIES 349
14.6.3 DYNAMIC COMPANIES 349
14.6.4 STARTING BLOCKS 349
14.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023 351
14.7 COMPANY VALUATION AND FINANCIAL METRICS 352
14.7.1 FINANCIAL METRICS 352
14.7.2 COMPANY VALUATION 353
14.8 BRAND/PRODUCT COMPARISON 354
14.9 COMPETITIVE SCENARIO 355
14.9.1 PRODUCT AND SOLUTION LAUNCHES 355
14.9.2 DEALS 356
14.9.3 EXPANSIONS 357
14.9.4 OTHER DEVELOPMENTS 358
15 COMPANY PROFILES 359
15.1 KEY PLAYERS 359
15.1.1 NVIDIA CORPORATION 359
15.1.1.1 Business overview 359
15.1.1.2 Products/Services/Solutions offered 360
15.1.1.3 Recent developments 361
15.1.1.3.1 Product and service launches 361
15.1.1.3.2 Deals 363
15.1.1.4 MnM view 367
15.1.1.4.1 Right to win 367
15.1.1.4.2 Strategic choices 367
15.1.1.4.3 Weaknesses and competitive threats 367
15.1.2 EXSCIENTIA 368
15.1.2.1 Business overview 368
15.1.2.2 Products/Services/Solutions offered 369
15.1.2.3 Recent developments 371
15.1.2.3.1 Solution launches 371
15.1.2.3.2 Deals 371
15.1.2.3.3 Expansions 377
15.1.2.3.4 Other developments 378
15.1.2.4 MnM view 379
15.1.2.4.1 Right to win 379
15.1.2.4.2 Strategic choices 379
15.1.2.4.3 Weaknesses and competitive threats 379
?
15.1.3 GOOGLE 380
15.1.3.1 Business overview 380
15.1.3.2 Products/Services/Solutions offered 381
15.1.3.3 Recent developments 382
15.1.3.3.1 Solution launches 382
15.1.3.3.2 Deals 383
15.1.3.3.3 Expansions 384
15.1.3.4 MnM view 384
15.1.3.4.1 Right to win 384
15.1.3.4.2 Strategic choices 384
15.1.3.4.3 Weaknesses and competitive threats 384
15.1.4 RECURSION 385
15.1.4.1 Business overview 385
15.1.4.2 Products/Services/Solutions offered 386
15.1.4.3 Recent developments 386
15.1.4.3.1 Solution launches 386
15.1.4.3.2 Deals 387
15.1.4.3.3 Expansions 388
15.1.4.4 MnM view 389
15.1.4.4.1 Right to win 389
15.1.4.4.2 Strategic choices made 389
15.1.4.4.3 Weaknesses and competitive threats 389
15.1.5 INSILICO MEDICINE 390
15.1.5.1 Business overview 390
15.1.5.2 Products/Services/Solutions offered 390
15.1.5.3 Recent developments 392
15.1.5.3.1 Product and solution launches and developments 392
15.1.5.3.2 Deals 393
15.1.5.3.3 Other developments 398
15.1.5.4 MnM view 399
15.1.5.4.1 Right to win 399
15.1.5.4.2 Strategic choices 399
15.1.5.4.3 Weaknesses and competitive threats 399
15.1.6 SCHR?DINGER, INC. 400
15.1.6.1 Business overview 400
15.1.6.2 Products/Services/Solutions offered 401
15.1.6.3 Recent developments 402
15.1.6.3.1 Deals 402
15.1.6.3.2 Other developments 405
?
15.1.7 BENEVOLENTAI 406
15.1.7.1 Business overview 406
15.1.7.2 Products/Services/Solutions offered 407
15.1.7.3 Recent developments 407
15.1.7.3.1 Deals 407
15.1.8 MICROSOFT CORPORATION 409
15.1.8.1 Business overview 409
15.1.8.2 Products/Services/Solutions offered 410
15.1.8.3 Recent developments 411
15.1.8.3.1 Deals 411
15.1.9 ATOMWISE INC. 413
15.1.9.1 Business overview 413
15.1.9.2 Products/Services/Solutions offered 413
15.1.9.3 Recent developments 414
15.1.9.3.1 Deals 414
15.1.10 ILLUMINA, INC. 415
15.1.10.1 Business overview 415
15.1.10.2 Products/Services/Solutions offered 416
15.1.10.3 Recent developments 417
15.1.10.3.1 Solution launches 417
15.1.10.3.2 Deals 418
15.1.11 NUMEDII, INC. 420
15.1.11.1 Business overview 420
15.1.11.2 Products/Services/Solutions offered 420
15.1.12 XTALPI INC. 421
15.1.12.1 Business overview 421
15.1.12.2 Products/Services/Solutions offered 421
15.1.12.3 Recent developments 422
15.1.12.3.1 Deals 422
15.1.13 IKTOS 424
15.1.13.1 Business overview 424
15.1.13.2 Products/Services/Solutions offered 425
15.1.13.3 Recent developments 426
15.1.13.3.1 Deals 426
15.1.13.3.2 Other developments 429
15.1.14 TEMPUS 430
15.1.14.1 Business overview 430
15.1.14.2 Products/Services/Solutions offered 430
15.1.14.3 Recent developments 431
15.1.14.3.1 Solution launches 431
15.1.14.3.2 Deals 432
15.1.14.3.3 Expansions 435
15.1.14.3.4 Other developments 435
15.1.15 DEEP GENOMICS 436
15.1.15.1 Business overview 436
15.1.15.2 Products/Services/Solutions offered 436
15.1.15.3 Recent developments 437
15.1.15.3.1 Solution launches 437
15.1.15.3.2 Deals 437
15.1.15.3.3 Other developments 437
15.1.16 VERGE GENOMICS 438
15.1.16.1 Business overview 438
15.1.16.2 Products/Services/Solutions offered 438
15.1.16.3 Recent developments 439
15.1.16.3.1 Deals 439
15.1.17 BENCHSCI 440
15.1.17.1 Business overview 440
15.1.17.2 Products/Services/Solutions offered 440
15.1.17.3 Recent developments 441
15.1.17.3.1 Solution launches 441
15.1.17.3.2 Deals 441
15.1.17.3.3 Other developments 441
15.1.18 INSITRO 442
15.1.18.1 Business overview 442
15.1.18.2 Products/Services/Solutions offered 442
15.1.18.3 Recent developments 443
15.1.18.3.1 Deals 443
15.1.18.3.2 Other developments 443
15.1.19 VALO HEALTH 444
15.1.19.1 Business overview 444
15.1.19.2 Products/Services/Solutions offered 444
15.1.19.3 Recent developments 445
15.1.19.3.1 Deals 445
15.1.19.3.2 Other developments 446
15.1.20 BPGBIO, INC. 447
15.1.20.1 Business overview 447
15.1.20.2 Products/Services/Solutions offered 447
15.1.20.3 Recent developments 448
15.1.20.3.1 Deals 448
15.1.21 MERCK KGAA 449
15.1.21.1 Business overview 449
15.1.21.2 Products/Services/Solutions offered 450
15.1.21.3 Recent developments 451
15.1.21.3.1 Solution launches 451
15.1.21.3.2 Deals 451
15.1.21.3.3 Expansions 452
15.1.21.3.4 Other developments 453
15.2 OTHER PLAYERS 454
15.2.1 PREDICTIVE ONCOLOGY 454
15.2.2 IQVIA INC. 455
15.2.3 TENCENT HOLDINGS LIMITED 456
15.2.4 CYTOREASON LTD. 457
15.2.5 OWKIN, INC. 458
15.2.6 CLOUD PHARMACEUTICALS 459
15.2.7 EVAXION BIOTECH A/S 460
15.2.8 STANDIGM INC. 461
15.2.9 BIOAGE LABS 462
15.2.10 ENVISAGENICS 463
15.2.11 ABCELLERA 464
15.2.12 CENTELLA 465
16 APPENDIX 466
16.1 DISCUSSION GUIDE 466
16.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 474
16.3 CUSTOMIZATION OPTIONS 476
16.4 RELATED REPORTS 476
16.5 AUTHOR DETAILS 477

List of Figures

FIGURE 1 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET: SEGMENTS AND REGIONS CONSIDERED 40
FIGURE 2 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET: YEARS CONSIDERED 42
FIGURE 3 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET: RESEARCH DESIGN 45
FIGURE 4 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET:
KEY DATA FROM SECONDARY SOURCES 47
FIGURE 5 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET: KEY PRIMARY SOURCES 48
FIGURE 6 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET:
KEY DATA FROM PRIMARY SOURCES 49
FIGURE 7 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET: KEY INDUSTRY INSIGHTS 50
FIGURE 8 BREAKDOWN OF PRIMARY INTERVIEWS: BY DEMAND SIDE, SUPPLY SIDE, DESIGNATION, AND REGION 50
FIGURE 9 RESEARCH METHODOLOGY: HYPOTHESIS BUILDING 51
FIGURE 10 SUPPLY-SIDE MARKET ESTIMATION: REVENUE SHARE ANALYSIS 52
FIGURE 11 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET: REVENUE SHARE ANALYSIS ILLUSTRATION 53
FIGURE 12 BOTTOM-UP APPROACH: END-USER SPENDING ON ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY 54
FIGURE 13 CAGR PROJECTIONS FROM ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES (2024–2029) 57
FIGURE 14 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS 58
FIGURE 15 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET: TOP-DOWN APPROACH 58
FIGURE 16 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET: DATA TRIANGULATION 59
FIGURE 17 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY PROCESS 2024 VS. 2029 (USD MILLION) 62
FIGURE 18 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY USE CASE 2024 VS. 2029 (USD MILLION) 63
FIGURE 19 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA, 2024 VS. 2029 (USD MILLION) 63
FIGURE 20 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY PLAYER TYPE 2024 VS. 2029 (USD MILLION) 64
FIGURE 21 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY AI TOOL 2024 VS. 2029 (USD MILLION) 65
FIGURE 22 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY DEPLOYMENT 2024 VS. 2029 (USD MILLION) 65
FIGURE 23 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER 2024 VS. 2029 (USD MILLION) 66
FIGURE 24 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET: REGIONAL SNAPSHOT 67
FIGURE 25 INCREASING NUMBER OF CROSS-INDUSTRY COLLABORATIONS AND PARTNERSHIPS TO DRIVE MARKET 68
FIGURE 26 US AND PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES COMMANDED LARGEST MARKET SHARE IN 2023 69
FIGURE 27 INDIA TO REGISTER HIGHEST GROWTH RATE FROM 2024 TO 2029 70
FIGURE 28 NORTH AMERICA TO DOMINATE MARKET DURING FORECAST PERIOD 71
FIGURE 29 EMERGING MARKETS TO REGISTER HIGHER GROWTH RATES DURING STUDY PERIOD 71
FIGURE 30 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 72
FIGURE 31 COST OF GENOME ANALYSIS VS. LEVELS OF RAW DATA GENERATED, 2003–2023 79
FIGURE 32 APPROVAL OF PERSONALIZED MEDICINES BY US FDA, 2015–2023 84
FIGURE 33 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET: TRENDS/DISRUPTIONS IMPACTING CUSTOMER’S BUSINESS 87
FIGURE 34 EVOLUTION OF AI IN DRUG DISCOVERY MARKET 88
FIGURE 35 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET: STRUCTURE-BASED DRUG DESIGNING 90
FIGURE 36 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET: ECOSYSTEM ANALYSIS 91
FIGURE 37 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET: SUPPLY CHAIN ANALYSIS 93
FIGURE 38 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET: TYPES OF SERVICE 94
FIGURE 39 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET: PORTER’S FIVE FORCES ANALYSIS 113
FIGURE 40 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR END USERS 115
FIGURE 41 KEY BUYING CRITERIA FOR TOP THREE END USERS 116
FIGURE 42 JURISDICTION ANALYSIS: TOP APPLICANT COUNTRIES FOR “AI IN DRUG DISCOVERY” PATENTS (JANUARY 2015–SEPTEMBER 2024) 117
FIGURE 43 MAJOR PATENTS IN ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET (JANUARY 2015–SEPTEMBER 2024) 119
FIGURE 44 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET: BUSINESS MODELS 130
FIGURE 45 BENEFITS OF HYBRID BUSINESS MODELS 131
FIGURE 46 SPECIALIZATION OF ARTIFICIAL INTELLIGENCE-BASED COMPANIES OVER TIME 131
FIGURE 47 FUNDING IN ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET 2013–2022 (USD MILLION) 132
FIGURE 48 MARKET POTENTIAL OF AI/GENERATIVE AI IN ENHANCING LABORATORY INFORMATICS ACROSS INDUSTRIES 134
FIGURE 49 IMPACT OF AI/GENERATIVE AI ON INTERCONNECTED AND ADJACENT ECOSYSTEMS 136
FIGURE 50 HIT-TO-LEAD IDENTIFICATION/LEAD GENERATION SEGMENT HELD LARGEST MARKET SHARE IN 2023 151
FIGURE 51 NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SNAPSHOT 215
FIGURE 52 DISTRIBUTION OF R&D COMPANIES, BY COUNTRY/REGION (2022 VS. 2023) 221
FIGURE 53 ASIA PACIFIC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SNAPSHOT 270
FIGURE 54 REVENUE ANALYSIS OF KEY PLAYERS IN ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET (2019–2023) 337
FIGURE 55 MARKET SHARE ANALYSIS OF KEY PLAYERS IN ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET (2023) 338
FIGURE 56 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET: RANKING OF KEY MARKET PLAYERS (2023) 339
FIGURE 57 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2023 341
FIGURE 58 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET: COMPANY FOOTPRINT 342
FIGURE 59 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2023 350
FIGURE 60 EV/EBITDA OF KEY VENDORS 352
FIGURE 61 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK
BETA OF KEY VENDORS 353
FIGURE 62 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET:
BRAND/PRODUCT COMPARATIVE ANALYSIS 354
FIGURE 63 NVIDIA CORPORATION: COMPANY SNAPSHOT 360
FIGURE 64 EXSCIENTIA: COMPANY SNAPSHOT 369
FIGURE 65 GOOGLE: COMPANY SNAPSHOT 381
FIGURE 66 RECURSION: COMPANY SNAPSHOT 385
FIGURE 67 SCHR?DINGER, INC.: COMPANY SNAPSHOT 401
FIGURE 68 BENEVOLENTAI: COMPANY SNAPSHOT 406
FIGURE 69 MICROSOFT CORPORATION: COMPANY SNAPSHOT 410
FIGURE 70 ILLUMINA, INC.: COMPANY SNAPSHOT 416
FIGURE 71 MERCK KGAA: COMPANY SNAPSHOT 450

List of Tables

TABLE 1 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET:
INCLUSIONS AND EXCLUSIONS 41
TABLE 2 EXCHANGE RATES UTILIZED FOR CONVERSION TO USD, 2021–2023 43
TABLE 3 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET: FACTOR ANALYSIS 56
TABLE 4 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET: MARKET SIZING ASSUMPTIONS 60
TABLE 5 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET: RISK ASSESSMENT 61
TABLE 6 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET: IMPACT ANALYSIS 73
TABLE 7 INDICATIVE LIST OF COLLABORATIONS AND PARTNERSHIPS, 2021–2023 74
TABLE 8 INDICATIVE LIST OF DRUGS LOSING PATENTS IN 2023 AND 2024 77
TABLE 9 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET: ROLE IN ECOSYSTEM 92
TABLE 10 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 104
TABLE 11 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 105
TABLE 12 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 106
TABLE 13 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 106
TABLE 14 MIDDLE EAST & AFRICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 107
TABLE 15 NORTH AMERICA: REGULATORY FRAMEWORK 107
TABLE 16 EUROPE: REGULATORY FRAMEWORK 108
TABLE 17 ASIA PACIFIC: REGULATORY FRAMEWORK 109
TABLE 18 MIDDLE EAST & AFRICA: REGULATORY FRAMEWORK 110
TABLE 19 LATIN AMERICA: REGULATORY FRAMEWORK 110
TABLE 20 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET: INDICATIVE SELLING PRICE, BY REGION, 2021–2023 111
TABLE 21 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET: INDICATIVE PRICING BY PROCESS, 2023 112
TABLE 22 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET: PORTER’S FIVE FORCES ANALYSIS 113
TABLE 23 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF TOP
THREE END USERS (%) 116
TABLE 24 KEY BUYING CRITERIA FOR TOP THREE END USERS 117
TABLE 25 JURISDICTION ANALYSIS OF TOP APPLICANT COUNTRIES FOR ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY 118
TABLE 26 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET: LIST OF PATENTS/PATENT APPLICATIONS 120
TABLE 27 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET: KEY CONFERENCES & EVENTS, JANUARY 2024–DECEMBER 2025 124
TABLE 28 CASE STUDY 1: LEVERAGING AI-DRIVEN PRECISION MEDICINE TO IDENTIFY PATIENT SUBTYPES AND NOVEL TARGETS IN INFLAMMATORY BOWEL DISEASE 125
TABLE 29 CASE STUDY 2: ARTIFICIAL INTELLIGENCE-DRIVEN DRUG DISCOVERY
AND CO-DEVELOPMENT 126
TABLE 30 CASE STUDY 3: ADVANCING GENE THERAPY FOR RARE NEUROLOGICAL DISEASES 127
TABLE 31 CASE STUDY 4: ARTIFICIAL INTELLIGENCE DESIGN AND OPTIMIZATION OF EXS4318 128
TABLE 32 CASE STUDY 5: ARTIFICIAL INTELLIGENCE-DRIVEN DESIGN AND CLINICAL EVALUATION OF GTAEXS617 129
TABLE 33 KEY ARTIFICIAL INTELLIGENCE-DERIVED CLINICAL ASSETS, BY COMPANY 140
TABLE 34 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY PROCESS 2022–2029 (USD MILLION) 151
TABLE 35 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR TARGET IDENTIFICATION & SELECTION, BY REGION, 2022–2029 (USD MILLION) 153
TABLE 36 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR TARGET VALIDATION, BY REGION, 2022–2029 (USD MILLION) 154
TABLE 37 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR HIT IDENTIFICATION & PRIORITIZATION, BY REGION, 2022–2029 (USD MILLION) 155
TABLE 38 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR HIT-TO-LEAD IDENTIFICATION/LEAD GENERATION, BY REGION, 2022–2029 (USD MILLION) 156
TABLE 39 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR LEAD OPTIMIZATION, BY REGION, 2022–2029 (USD MILLION) 157
TABLE 40 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR CANDIDATE SELECTION & VALIDATION, BY REGION, 2022–2029 (USD MILLION) 158
TABLE 41 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY USE CASE, 2022–2029 (USD MILLION) 160
TABLE 42 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR UNDERSTANDING DISEASES, BY REGION, 2022–2029 (USD MILLION) 162
TABLE 43 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR DRUG REPURPOSING, BY REGION, 2022–2029 (USD MILLION) 163
TABLE 44 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR DE NOVO DRUG DESIGN, BY TYPE, 2022–2029 (USD MILLION) 163
TABLE 45 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR DE NOVO DRUG DESIGN, BY REGION, 2022–2029 (USD MILLION) 164
TABLE 46 SMALL-MOLECULE DESIGN MARKET, BY REGION, 2022–2029 (USD MILLION) 164
TABLE 47 VACCINE DESIGN MARKET, BY REGION, 2022–2029 (USD MILLION) 165
TABLE 48 ANTIBODY & OTHER BIOLOGICS DESIGN MARKET, BY REGION 2022–2029 (USD MILLION) 166
TABLE 49 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR DRUG OPTIMIZATION, BY TYPE, 2022–2029 (USD MILLION) 166
TABLE 50 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR DRUG OPTIMIZATION, BY REGION, 2022–2029 (USD MILLION) 167
TABLE 51 SMALL-MOLECULE OPTIMIZATION MARKET, BY REGION 2022–2029 (USD MILLION) 168
TABLE 52 VACCINE OPTIMIZATION MARKET, BY REGION, 2022–2029 (USD MILLION) 169
TABLE 53 ANTIBODY & OTHER BIOLOGICS OPTIMIZATION MARKET, BY REGION 2022–2029 (USD MILLION) 170
TABLE 54 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR SAFETY & TOXICITY, BY REGION, 2022–2029 (USD MILLION) 171
TABLE 55 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA, 2022–2029 (USD MILLION) 173
TABLE 56 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR ONCOLOGY BY REGION, 2022–2029 (USD MILLION) 175
TABLE 57 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR INFECTIOUS DISEASES, BY REGION, 2022–2029 (USD MILLION) 176
TABLE 58 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR NEUROLOGY BY REGION, 2022–2029 (USD MILLION) 177
TABLE 59 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR METABOLIC DISEASES, BY REGION, 2022–2029 (USD MILLION) 178
TABLE 60 INDICATIVE LIST OF DEVELOPMENTS IN CARDIOVASCULAR DRUG DEVELOPMENT 179
TABLE 61 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR CARDIOVASCULAR DISEASES, BY REGION, 2022–2029 (USD MILLION) 179
TABLE 62 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR IMMUNOLOGY BY REGION, 2022–2029 (USD MILLION) 180
TABLE 63 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR MENTAL HEALTH DISORDERS, BY REGION, 2022–2029 (USD MILLION) 181
TABLE 64 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR OTHER THERAPEUTIC AREAS, BY REGION, 2022–2029 (USD MILLION) 181
TABLE 65 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY PLAYER TYPE 2022–2029 (USD MILLION) 183
TABLE 66 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR END-TO-END SOLUTION PROVIDERS, BY REGION, 2022–2029 (USD MILLION) 184
TABLE 67 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR NICHE/POINT SOLUTION PROVIDERS, BY REGION, 2022–2029 (USD MILLION) 185
TABLE 68 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR AI TECHNOLOGY PROVIDERS, BY REGION, 2022–2029 (USD MILLION) 186
TABLE 69 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR BUSINESS PROCESS SERVICE PROVIDERS, BY REGION, 2022–2029 (USD MILLION) 186
TABLE 70 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY AI TOOL 2022–2029 (USD MILLION) 188
TABLE 71 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR MACHINE LEARNING, BY TYPE, 2022–2029 (USD MILLION) 189
TABLE 72 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR MACHINE LEARNING, BY REGION, 2022–2029 (USD MILLION) 190
TABLE 73 DEEP LEARNING MARKET, BY REGION, 2022–2029 (USD MILLION) 192
TABLE 74 SUPERVISED LEARNING MARKET, BY REGION, 2022–2029 (USD MILLION) 193
TABLE 75 REINFORCEMENT LEARNING MARKET, BY REGION, 2022–2029 (USD MILLION) 194
TABLE 76 UNSUPERVISED LEARNING MARKET, BY REGION, 2022–2029 (USD MILLION) 195
TABLE 77 OTHER MACHINE LEARNING TECHNOLOGIES MARKET, BY REGION 2022–2029 (USD MILLION) 195
TABLE 78 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR NATURAL LANGUAGE PROCESSING, BY REGION, 2022–2029 (USD MILLION) 196
TABLE 79 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR CONTEXT-AWARE PROCESSING & COMPUTING, BY REGION, 2022–2029 (USD MILLION) 197
TABLE 80 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR COMPUTER VISION, BY REGION, 2022–2029 (USD MILLION) 198
TABLE 81 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR IMAGE ANALYSIS BY REGION, 2022–2029 (USD MILLION) 199
TABLE 82 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY DEPLOYMENT 2022–2029 (USD MILLION) 201
TABLE 83 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR ON-PREMISES DEPLOYMENT, BY REGION, 2022–2029 (USD MILLION) 202
TABLE 84 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR CLOUD-BASED DEPLOYMENT, BY REGION, 2022–2029 (USD MILLION) 203
TABLE 85 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR SAAS-BASED DEPLOYMENT, BY REGION, 2022–2029 (USD MILLION) 205
TABLE 86 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER 2022–2029 (USD MILLION) 207
TABLE 87 INDICATIVE LIST OF DEVELOPMENTS RELATED TO ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL & BIOTECHNOLOGY INDUSTRY 208
TABLE 88 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2022–2029 (USD MILLION) 209
TABLE 89 INDICATIVE LIST OF COLLABORATIONS WITH CONTRACT RESEARCH ORGANIZATIONS 210
TABLE 90 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2022–2029 (USD MILLION) 211
TABLE 91 INDICATIVE LIST OF COLLABORATIONS IN RESEARCH CENTERS AND ACADEMIC & GOVERNMENT INSTITUTES 211
TABLE 92 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR RESEARCH CENTERS AND ACADEMIC & GOVERNMENT INSTITUTES, BY REGION, 2022–2029 (USD MILLION) 212
TABLE 93 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY REGION 2022–2029 (USD MILLION) 214
TABLE 94 NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET BY COUNTRY, 2022–2029 (USD MILLION) 216
TABLE 95 NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET BY PROCESS 2022–2029 (USD MILLION) 216
TABLE 96 NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET BY USE CASE, 2022–2029 (USD MILLION) 217
TABLE 97 NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR DE NOVO DRUG DESIGN, BY TYPE, 2022–2029 (USD MILLION) 217
TABLE 98 NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR DRUG OPTIMIZATION, BY TYPE, 2022–2029 (USD MILLION) 217
TABLE 99 NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET BY THERAPEUTIC AREA, 2022–2029 (USD MILLION) 218
TABLE 100 NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET BY PLAYER TYPE, 2022–2029 (USD MILLION) 218
TABLE 101 NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET BY AI TOOL, 2022–2029 (USD MILLION) 219
TABLE 102 NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR MACHINE LEARNING, BY TYPE, 2022–2029 (USD MILLION) 219
TABLE 103 NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET BY DEPLOYMENT, 2022–2029 (USD MILLION) 220
TABLE 104 NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET BY END USER, 2022–2029 (USD MILLION) 220
TABLE 105 US: INDICATIVE LIST OF STRATEGIC DEVELOPMENTS 221
TABLE 106 US: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY PROCESS
2022–2029 (USD MILLION) 222
TABLE 107 US: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY USE CASE 2022–2029 (USD MILLION) 223
TABLE 108 US: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR DE NOVO DRUG DESIGN, BY TYPE, 2022–2029 (USD MILLION) 223
TABLE 109 US: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR DRUG OPTIMIZATION, BY TYPE, 2022–2029 (USD MILLION) 223
TABLE 110 US: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA, 2022–2029 (USD MILLION) 224
TABLE 111 US: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY PLAYER TYPE, 2022–2029 (USD MILLION) 224
TABLE 112 US: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY AI TOOL 2022–2029 (USD MILLION) 225
TABLE 113 US: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR MACHINE LEARNING, BY TYPE, 2022–2029 (USD MILLION) 225
TABLE 114 US: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY DEPLOYMENT, 2022–2029 (USD MILLION) 226
TABLE 115 US: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2022–2029 (USD MILLION) 226
TABLE 116 CANADA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY PROCESS 2022–2029 (USD MILLION) 227
TABLE 117 CANADA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY USE CASE, 2022–2029 (USD MILLION) 228
TABLE 118 CANADA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR
DE NOVO DRUG DESIGN, BY TYPE, 2022–2029 (USD MILLION) 228
TABLE 119 CANADA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR DRUG OPTIMIZATION, BY TYPE, 2022–2029 (USD MILLION) 228
TABLE 120 CANADA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET BY THERAPEUTIC AREA, 2022–2029 (USD MILLION) 229
TABLE 121 CANADA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY PLAYER TYPE, 2022–2029 (USD MILLION) 229
TABLE 122 CANADA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY AI TOOL, 2022–2029 (USD MILLION) 230
TABLE 123 CANADA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR MACHINE LEARNING, BY TYPE, 2022–2029 (USD MILLION) 230
TABLE 124 CANADA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY DEPLOYMENT, 2022–2029 (USD MILLION) 231
TABLE 125 CANADA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2022–2029 (USD MILLION) 231
TABLE 126 EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY COUNTRY 2022–2029 (USD MILLION) 232
TABLE 127 EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY PROCESS, 2022–2029 (USD MILLION) 233
TABLE 128 EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY USE CASE, 2022–2029 (USD MILLION) 233
TABLE 129 EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR DE NOVO DRUG DESIGN, BY TYPE, 2022–2029 (USD MILLION) 234
TABLE 130 EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR DRUG OPTIMIZATION, BY TYPE, 2022–2029 (USD MILLION) 234
TABLE 131 EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET BY THERAPEUTIC AREA, 2022–2029 (USD MILLION) 235
TABLE 132 EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY PLAYER TYPE, 2022–2029 (USD MILLION) 235
TABLE 133 EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY AI TOOL, 2022–2029 (USD MILLION) 236
TABLE 134 EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR MACHINE LEARNING, BY TYPE, 2022–2029 (USD MILLION) 236
TABLE 135 EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET BY DEPLOYMENT, 2022–2029 (USD MILLION) 237
TABLE 136 EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET BY END USER, 2022–2029 (USD MILLION) 237
TABLE 137 UK: INDICATIVE LIST OF STRATEGIC DEVELOPMENTS 238
TABLE 138 UK: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY PROCESS 2022–2029 (USD MILLION) 239
TABLE 139 UK: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY USE CASE, 2022–2029 (USD MILLION) 239
TABLE 140 UK: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR DE NOVO DRUG DESIGN, BY TYPE, 2022–2029 (USD MILLION) 240
TABLE 141 UK: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR DRUG OPTIMIZATION, BY TYPE, 2022–2029 (USD MILLION) 240
TABLE 142 UK: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA, 2022–2029 (USD MILLION) 241
TABLE 143 UK: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY PLAYER TYPE, 2022–2029 (USD MILLION) 241
TABLE 144 UK: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY AI TOOL 2022–2029 (USD MILLION) 242
TABLE 145 UK: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR MACHINE LEARNING, BY TYPE, 2022–2029 (USD MILLION) 242
TABLE 146 UK: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY DEPLOYMENT, 2022–2029 (USD MILLION) 243
TABLE 147 UK: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2022–2029 (USD MILLION) 243
TABLE 148 GERMANY: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY PROCESS, 2022–2029 (USD MILLION) 244
TABLE 149 GERMANY: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY USE CASE, 2022–2029 (USD MILLION) 244
TABLE 150 GERMANY: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR DE NOVO DRUG DESIGN, BY TYPE, 2022–2029 (USD MILLION) 245
TABLE 151 GERMANY: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR DRUG OPTIMIZATION, BY TYPE, 2022–2029 (USD MILLION) 245
TABLE 152 GERMANY: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA, 2022–2029 (USD MILLION) 246
TABLE 153 GERMANY: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY PLAYER TYPE, 2022–2029 (USD MILLION) 246
TABLE 154 GERMANY: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY AI TOOL, 2022–2029 (USD MILLION) 247
TABLE 155 GERMANY: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR MACHINE LEARNING, BY TYPE, 2022–2029 (USD MILLION) 247
TABLE 156 GERMANY: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET BY DEPLOYMENT, 2022–2029 (USD MILLION) 248
TABLE 157 GERMANY: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2022–2029 (USD MILLION) 248
TABLE 158 FRANCE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY PROCESS, 2022–2029 (USD MILLION) 249
TABLE 159 FRANCE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY USE CASE, 2022–2029 (USD MILLION) 250
TABLE 160 FRANCE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR DE NOVO DRUG DESIGN, BY TYPE, 2022–2029 (USD MILLION) 250
TABLE 161 FRANCE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR DRUG OPTIMIZATION, BY TYPE, 2022–2029 (USD MILLION) 250
TABLE 162 FRANCE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET BY THERAPEUTIC AREA, 2022–2029 (USD MILLION) 251
TABLE 163 FRANCE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY PLAYER TYPE, 2022–2029 (USD MILLION) 251
TABLE 164 FRANCE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY AI TOOL, 2022–2029 (USD MILLION) 252
TABLE 165 FRANCE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR MACHINE LEARNING, BY TYPE, 2022–2029 (USD MILLION) 252
TABLE 166 FRANCE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET BY DEPLOYMENT, 2022–2029 (USD MILLION) 253
TABLE 167 FRANCE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2022–2029 (USD MILLION) 253
TABLE 168 ITALY: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY PROCESS, 2022–2029 (USD MILLION) 254
TABLE 169 ITALY: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY USE CASE, 2022–2029 (USD MILLION) 255
TABLE 170 ITALY: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR DE NOVO DRUG DESIGN, BY TYPE, 2022–2029 (USD MILLION) 255
TABLE 171 ITALY: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR DRUG OPTIMIZATION, BY TYPE, 2022–2029 (USD MILLION) 255
TABLE 172 ITALY: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA, 2022–2029 (USD MILLION) 256
TABLE 173 ITALY: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY PLAYER TYPE, 2022–2029 (USD MILLION) 256
TABLE 174 ITALY: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY AI TOOL, 2022–2029 (USD MILLION) 257
TABLE 175 ITALY: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR MACHINE LEARNING, BY TYPE, 2022–2029 (USD MILLION) 257
TABLE 176 ITALY: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY DEPLOYMENT, 2022–2029 (USD MILLION) 258
TABLE 177 ITALY: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2022–2029 (USD MILLION) 258
TABLE 178 SPAIN: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY PROCESS, 2022–2029 (USD MILLION) 259
TABLE 179 SPAIN: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY USE CASE, 2022–2029 (USD MILLION) 259
TABLE 180 SPAIN: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR DE NOVO DRUG DESIGN, BY TYPE, 2022–2029 (USD MILLION) 260
TABLE 181 SPAIN: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR DRUG OPTIMIZATION, BY TYPE, 2022–2029 (USD MILLION) 260
TABLE 182 SPAIN: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA, 2022–2029 (USD MILLION) 261
TABLE 183 SPAIN: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY PLAYER TYPE, 2022–2029 (USD MILLION) 261
TABLE 184 SPAIN: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY AI TOOL, 2022–2029 (USD MILLION) 262
TABLE 185 SPAIN: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR MACHINE LEARNING, BY TYPE, 2022–2029 (USD MILLION) 262
TABLE 186 SPAIN: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY DEPLOYMENT, 2022–2029 (USD MILLION) 263
TABLE 187 SPAIN: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2022–2029 (USD MILLION) 263
TABLE 188 REST OF EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET BY PROCESS, 2022–2029 (USD MILLION) 264
TABLE 189 REST OF EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET BY USE CASE, 2022–2029 (USD MILLION) 264
TABLE 190 REST OF EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR DE NOVO DRUG DESIGN, BY TYPE, 2022–2029 (USD MILLION) 265
TABLE 191 REST OF EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR DRUG OPTIMIZATION, BY TYPE, 2022–2029 (USD MILLION) 265
TABLE 192 REST OF EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET BY THERAPEUTIC AREA, 2022–2029 (USD MILLION) 266
TABLE 193 REST OF EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET BY PLAYER TYPE, 2022–2029 (USD MILLION) 266
TABLE 194 REST OF EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET BY AI TOOL, 2022–2029 (USD MILLION) 267
TABLE 195 REST OF EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR MACHINE LEARNING, BY TYPE, 2022–2029 (USD MILLION) 267
TABLE 196 REST OF EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET BY DEPLOYMENT, 2022–2029 (USD MILLION) 268
TABLE 197 REST OF EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET BY END USER, 2022–2029 (USD MILLION) 268
TABLE 198 ASIA PACIFIC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET BY COUNTRY 2022–2029 (USD MILLION) 270
TABLE 199 ASIA PACIFIC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET BY PROCESS, 2022–2029 (USD MILLION) 271
TABLE 200 ASIA PACIFIC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET BY USE CASE, 2022–2029 (USD MILLION) 271
TABLE 201 ASIA PACIFIC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET
FOR DE NOVO DRUG DESIGN, BY TYPE, 2022–2029 (USD MILLION) 272
TABLE 202 ASIA PACIFIC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR DRUG OPTIMIZATION, BY TYPE, 2022–2029 (USD MILLION) 272
TABLE 203 ASIA PACIFIC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET BY THERAPEUTIC AREA, 2022–2029 (USD MILLION) 273
TABLE 204 ASIA PACIFIC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET BY PLAYER TYPE, 2022–2029 (USD MILLION) 273
TABLE 205 ASIA PACIFIC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET BY AI TOOL, 2022–2029 (USD MILLION) 274
TABLE 206 ASIA PACIFIC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR MACHINE LEARNING, BY TYPE, 2022–2029 (USD MILLION) 274
TABLE 207 ASIA PACIFIC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET BY DEPLOYMENT, 2022–2029 (USD MILLION) 275
TABLE 208 ASIA PACIFIC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2022–2029 (USD MILLION) 275
TABLE 209 JAPAN: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY PROCESS, 2022–2029 (USD MILLION) 277
TABLE 210 JAPAN: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY USE CASE, 2022–2029 (USD MILLION) 277
TABLE 211 JAPAN: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR DE NOVO DRUG DESIGN, BY TYPE, 2022–2029 (USD MILLION) 278
TABLE 212 JAPAN: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR DRUG OPTIMIZATION, BY TYPE, 2022–2029 (USD MILLION) 278
TABLE 213 JAPAN: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA, 2022–2029 (USD MILLION) 279
TABLE 214 JAPAN: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY PLAYER TYPE, 2022–2029 (USD MILLION) 279
TABLE 215 JAPAN: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY AI TOOL, 2022–2029 (USD MILLION) 280
TABLE 216 JAPAN: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR MACHINE LEARNING, BY TYPE, 2022–2029 (USD MILLION) 280
TABLE 217 JAPAN: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY DEPLOYMENT, 2022–2029 (USD MILLION) 281
TABLE 218 JAPAN: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2022–2029 (USD MILLION) 281
TABLE 219 CHINA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY PROCESS, 2022–2029 (USD MILLION) 282
TABLE 220 CHINA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY USE CASE, 2022–2029 (USD MILLION) 283
TABLE 221 CHINA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR DE NOVO DRUG DESIGN, BY TYPE, 2022–2029 (USD MILLION) 283
TABLE 222 CHINA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR DRUG OPTIMIZATION, BY TYPE, 2022–2029 (USD MILLION) 283
TABLE 223 CHINA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA, 2022–2029 (USD MILLION) 284
TABLE 224 CHINA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY PLAYER TYPE, 2022–2029 (USD MILLION) 284
TABLE 225 CHINA: ARTIFICIAL INT